Chemotherapy-induced peripheral neurotoxicity

Expert Opinion on Drug Safety

Volumn 3, Issue 6, 2004, Pages 535-546

  Cavaletti, Guido ^a   Marmiroli, Paola ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Chemotherapy; Neuropathy; Neurotoxicity

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DIMESNA; DOCETAXEL; EPOTHILONE B; EPOTHILONE DERIVATIVE; GLUTAMINE; IXABEPILONE; LEUKEMIA INHIBITORY FACTOR; NAVELBINE; NEDAPLATIN; NEUROPROTECTIVE AGENT; OXALIPLATIN; PACLITAXEL; PLATINUM 1,2 DIAMINOCYCLOHEXANE; PLATINUM DERIVATIVE; PROTEASOME INHIBITOR; SOMATOMEDIN C; SURAMIN; TAXANE DERIVATIVE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ATAXIA; BILIARY EXCRETION; BIRTH DEFECT; BLADDER DYSFUNCTION; BODY POSITION; BONE MARROW TOXICITY; CANCER PATIENT; CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CORTI ORGAN; DISEASE SEVERITY; DNA ADDUCT; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TRANSFORMATION; DYSESTHESIA; ERECTILE DYSFUNCTION; FINGER; GAIT DISORDER; GUILLAIN BARRE SYNDROME; HUMAN; HYPESTHESIA; INCIDENCE; LOW DRUG DOSE; MEGACOLON; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUTH DISEASE; MUSCLE CRAMP; MUSCLE DENERVATION; MUSCLE SPASM; MUSCLE WEAKNESS; MYELOMA; NEPHROTOXICITY; NEUROPHYSIOLOGY; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARALYTIC ILEUS; PARESTHESIA; PERCEPTION DISORDER; PERIPHERAL NEUROPATHY; POLYRADICULONEUROPATHY; QUADRIPLEGIA; QUALITY OF LIFE; REFLEX DISORDER; REVIEW; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SKIN MANIFESTATION; SKIN TINGLING; SOLID TUMOR; SPINAL NERVE; TENDON REFLEX; TOE; UPPER RESPIRATORY TRACT; URINARY EXCRETION; VIBRATION SENSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; EPOTHILONES; HUMANS; NEOPLASMS; NEUROPROTECTIVE AGENTS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASE INHIBITORS; SURAMIN; TAXOIDS; THALIDOMIDE;

EID: 8844232619     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.6.535     Document Type: Review

References (98)

1. QUASTHOFF S, HARTUNG HP: Chemotherapy-induced peripheral neuropathy. J. Neurol. (2002) 249(1):9-17.
2. WINDEBANK AJ: Chemotherapeutic neuropathy. Curr. Opin. Neurol. (1999) 12(5):565-571.
3. HARTMANNN JT, LIPP HP: Toxicity of platinum compounds. Expert Opin. Pharmacother. (2003) 4(6):889-901.
4. GO RS, ADJEI AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. (1999) 17(1):409-422.
5. WOLOSCHUK DM, PRUEMER JM, CLUXTON RJ Jr: Carboplatin: new cisplatin analog. Drug Intell. Clin. Pharmacol. (1982) 22 11):843-849.
6. CULY CR, CLEMETT D, WISEMAN LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs (2000) 60 4):895-924.
7. RAYMOND E, CHANEY SG, TAAMMA A, CVITKOVIC E: Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. (1998) 9 10):1053-1071.
8. REED E, YUSPA SH, ZWELLING LA, OZOLS RF, POIRIER MC: Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients. J. Clin. Invest. (1986) 77(2):545-550.
9. POIRIER MC, REED E, LITTERST CL, KATZ D, GUPTS-BURT S: Persistence of platinum-ammine-DNA adducts in gonads and kidney of rats and multiple tissues from cancer patients. Cancer Res. (1992) 52 1):149-153.
10. POIRIER MC, REED E, ZWELLING LA, OZOLS RF, LITTERST CL, YUSPA SH: Polyclonal antibodies to quantitate cis-diamminedichloroplatinum II-DNA-adducts in cancer patients and in animal models. Environ. Health Perspect. (1985) 62:89-94.
11. WISEMAN LR, ADKINS JC, PLOSKER GL, GOA KL: Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Drugs Ageing (1999) 14(6):459-475.
12. MEIJER C, DE VRIES EG, MARMIROLI P, TREDICI G, FRATTOLA L, CAVALETTI G: Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicol. (1999) 20 6):883-887.
13. SCOTT RH, WOODS AJ, LACEY MJ, FERNANDO D, CRAWFORD JH, ANDREWS PL: An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats. Naunyn. Schmiedebergs Arch. Pharmacol. (1995) 352(3):247-255.
14. GILL JS, WINDEBANK AJ: Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J. Clin. Inv. (1998) 101(12):2842-2850.
15. CVITKOVIC E: Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat. Rev. (1998) 24 4):265-281.
16. LOUVET C, LORANGE A, LETTENDRE F et al.: Acute and delayed emesis after cisplatin-based regimen: description and prevention. Oncology (1991) 48(5):392-396.
17. TOMIWA KC, NOLAN C, CAVANAGH JB: The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol. (1986) 69(3-4):295-308.
18. CAVALETTI G, TREDICI G, MARMIROLI P, PETRUCCIOLI MG, BARAJON I, FABBRICA D: Morphometric study of the sensory neurones and peripheral nerve changes induced by chronic cisplatin (DDP) administration. Acta Neuropathol. (1992) 84(4):364-371.
19. CECE R, PETRUCCIOLI MG, PIZZINI G, CAVALETTI G, TREDICI G: Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. J. Submicr. Cytol. Pathol. (1995) 27 (4):417-425.
20. MOLLMAN JE: Cisplatin neurotoxicity. N. Engl. J. Med. (1990) 322(2):126-127.
21. SIEGAL T, HAIM N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer (1990) 66(6):1117-1123.
22. GRUNBERG SM, SONKA S, STEVENSON LL, MUGGIA FM: Progressive paraesthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother. Pharmacol. (1989) 25(1):62-64.
23. CAVALETTI G, TREDICI G, MARMIROLI P, FABBRICA D, BRAGA M: Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats in vivo. (1994) 8(3):313-316.
24. 2 over 3 h) employed in the treatment of gynecologic malignancies. J. Cancer Res. Clin. Oncol. (2001) 127(1 ):55-58.
25. CAVALETTI G, BOGLIUN G, ZINCONE A et al.: Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anti-Cancer Res. (1998) 18(5B):3797-3802.
26. CAVALETTI G, FABBRICA D, MINOIA C, FRATTOLA L, TREDICI G: Carboplatin toxic effects on the peripheral nervous system of the rat. Ann. Oncol. (1998) 9(4):443-447.
27. WILSON RH, LEHKY T, THOMAS RR et al.: Acute oxaliplatin brain-induced peripheral nerve hyperexcitability. J. Clin. Oncol. (2002) 20(7):1767-1774.
28. ECKEL F, SCHMELZ R, ADELSBERGER H et al.: Prevention of oxaliplatin-induced neuropathy by carbamazepine: a pilot study. Dtsch. Med. Wochenschr. (2002) 127(3):78-82.
29. GROTHEY A: Oxaliplatin-safety profile: neurotoxicity. Sem. Oncol. (2003) 30(4 Suppl. 15):5-13.
30. ADELSBERGER H, QUASTHOFF S, GROSSKKEUTZ J et al.: The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur. J. Pharmachol. (2000) 406 1):25-32.
31. GROLLEAU F, GAMELIN L, BOISDRON-CELLE M et al.: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. (2001) 85(5):2293-2297.
32. HAYAKAWA K, SOUBE G, ITOH T, MITSUMA T: Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol on adult rat sympathetic ganglion explants in vitro. Life Sci. (1994) 55 7):519-525.
33. KONINGS PN, MAKKINK WK, VAN DELFT AM, RUIGT GS: Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res. (1994) 640 1-2):195-204.
34. MALGRANGE B, DELRÉE P, RIGO JM, BARON H, MOONEN G: Image analysis of neurite regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and its prevention by nerve growth factor or fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J. Neurosci. Meth. (1994) 53(1):111-122.
35. WINDEBANK AJ, SMITH AG, RUSSELL JW: The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology (1994) 44(3Pt1):488-494.
36. GELDOF AA: Nerve-growth-factor-dependent neurite outgrowth assay: a research model for chemotherapy-induced neuropathy. J. Cancer Res. Clin. Oncol. (1995) 121(11):657-660.
37. APFEL SC, AREZZO JC, LIPSON LA, KESSLER JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol (1992) 31(1):76-80.
38. CAVALETTI G, MINOIA C, SCHIEPPATI M, TREDICI G: Protective effects of glutathione on cisplatin neurotoxicity in rats. Int. J. Rad. Oncol. Biol. Phys. (1994) 29(4):771-776.
39. GAO W-Q, DYBDAL N, SHINSKY N et al.: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. (1995) 38(1):30-37.
40. SCHMIDT Y, UNGER JW, BARTKE I, REITER R: Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp. Neurol. (1995) 132(1):16-23.
41. TREDICI G, BRAGA M, NICOLINI G et al.: Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp. Neurol. (1999) 159(2):551-558.
42. NO AUTHORS LISTED: Goodman & Gilman's pharmachological basis of therapeutics (10th edn). Hardman JG, Limbrid LE, Goodman Gilman A (Eds). McGraw-Hill Inc, New York (2001).
43. KEMPER EM, VAN ZANDEMBERGEN AE, CLEYPOOL C et al.: Increased penetration of paclitaxel into brain by inhibition of P-glycoprotein. Clin. Canc. Res. (2003) 9(7):2849-2855.
44. ROWINSKY EK, DONEHOWER RC: Antimicrotubule agents. In: Cancer chemotherapy and biotherapy (2nd edn). Chabner BA, Longo DL (Eds). Lippincott-Raven Publishers, Philadelphia, USA (1996):263-296.
45. BLAGOSKLONNY MV, SCHULTE T, NGUYEN P, TREPEL J, NECKERS LM: Taxol-induced apoptosis and phoshorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. (1996) 56(8):1851-1854.
46. CAVALETTI G, CAVALLETTI E, MONTAGUTI P, OGGIONI N, DE NEGRI O, TREDICI G: Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicol. (1997) 18(1):137-145.
47. SCHILLING T, HANAUSKE AR: Taxol-cisplatin neuropathy caused by membrane leak and axonal depolarization: an in vivo and in vitro study. J. Neurol. (1995) 242:145.
48. CANTA A, LANZANI A, GALBIATI S et al.: Rat in vivo models of taxanes' peripheral neurotoxicity following chronic intravenous administration. J. Periph. Nerv. Sys. (2004) 9 104
49. McLEOD JG, PENNY R: Vincristine neuropathy: an electrophysiological and histological study. J. Neurol. Neurosurg. Psychiat. (1969) 32(4):297-304.
50. POSTMA TJ, BENARD BA, HUIJGENS PC et al.: Long term effects of vincristine on the peripheral nervous system. J. Neurooncol. (1993) 15(1):23-27.
51. LA ROCCA RV, STEIN CA, DANESI R, MYERS CE: Suramin, a novel antitumor compound. J. Steroid Biochem. Mol. Biol. (1990) 37 6):893-898.
52. EISENBERGER MA, REYNO LM, JODRELL DI et al.: Suramin, an active drug for prostate cancer: interim observations in a Phase I trial. J. Natl. Cancer Inst. (1993) 85(8):611-621.
53. SUN X, WINDEBANK AJ: Calcium in suramin-induced rat sensory neuron toxicity in vitro. Brain Res. (1996) 742(1-2 ):149-156.
54. LAROCCA RV, MEER J, GILLIATT RW et al.: Suramin-induced polyneuropathy. Neurology (1990) 40(6):954-960.
55. CHAUDHRY V, EISENBERGER MA, SINIBALDI VJ et al.: A prospective study of suramin-induced peripheral neuropathy. Brain (1996) 119(Pt 6):2039-2052.
56. SOLIVEN B, DHAND UK, KOBAYASHI K et al.: Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve (1997) 20(1):83-91.
57. CONSTANTOPOULOS G, REES S, CRAGG BG et al.: Effect of suramin on the activities of degradative enzymes of sphingolipids in rats. Res. Commun. Chem. Pathol. Pharmacol. (1981) 32 1):87-97.
58. RUSSELL JW, GILL JS, SORENSON EJ et al.: Suramin-induced neuropathy in an animal model. J. Neurol. Sci. (2001) 192(1-2):71-80.
59. GARDNER-MEDWIN JM, SMITH NJ, POWELL RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Bechet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis. (1994) 53 828-832.
60. OCHONISKY S, VERROUST J, BASTUJI-GARIN S, GHERARDI R, REVUZ J: Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch. Dermatol. (1994) 130(1 ):66-69.
61. MOLLOY FM, FLOETER MK, SEYD NA et al.: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve (2001) 24(8):1050-1057.
62. BASTUJI-GARIN S, OCHONISKY S, BOUCHE P et al.: Incidence and risk factors for thalidomide neuropathy: prospective study of 135 dermatologic patients. J. Invest. Dermatol. (2002) 119 5):1020-1026.
63. CHAUDRY V, CORNBLATH DR, CORSE A, FREIMER M, SIMMONS-O'BRIEN E, VOGELSANG G: Thalidomide-induced neuropathy. Neurology (2003) 59(12):1872-1875.
64. CAVALETTI G, BERONIO A, RENI L et al.: Thalidomide sensory neurotoxicity: a clinical and neurophysiolgical study. Neurology (2004) 62(12):2291-2293.
65. GIANNINI F, VOLPI N, ROSSI S, PASSERO S, FIMIANI M, CERASE A: Thalidomide-induced neuropathy: a ganglionopathy? Neurology (2003) 60(5):877-878.
66. ABRAHAM, J, AGRAWAL M, BAKKE S et al.: Phase I clinical and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. 21(9):1866-1873.
67. MANI S, McDAID H, HAMILTON A et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B in solid tumors. Clin. Canc. Res. (2004) 10(4):1289-1298.
68. MITCHEL BS: The proteasome. An emerging therapeutic target in cancer. N. Engl. J. Med. (1993) 348(26):2597-2598.
69. RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractroy myeloma. N. Engl. J. Med. (1993) 348(26):2609-2617.
70. IMAJOH-OHMI S, KAWAGUCHI T, SUGIYAMA S et al.: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun. (1995) 217(3):1070-1077.
71. SHINOHARA K, TOMIOKA M, NAKANO H et al.: Apoptosis induction resulting from proteasome inhibition. Biochem. J. (1996) 317(Pt2):385-388.
72. HAMERS FP, PETTE C, NEIJT JP, GISPEN WH: The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. Eur. J. Pharmacol. (1993) 233(1):177-178.
73. VAN DER HOOP GR, HAMERS FP, NEIJT JP, VELDMAN M, GISPEN W, JENNEKENS FG: Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J. Neurol. Sci. (1994) 126(2):109-115.
74. VAN DER HOOP GR, VECHT CJ, VAN DER BURG ME et al.: Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N. Engl. J. Med. (1990) 322 2):89-94.
75. ROBERTS JA, JENISON EL, KIM K, CLARKE-PEARSON D, LANGLEBEN A: A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol. Oncol. (1997) 67(2):172-177.
76. KEMP G, ROSE P, LURAIN J et al.: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. (1996) 14 7):2101-2112.
77. MOORE DH, DONNELLY J, McGUIRE WP et al.: Limited access trial using amifostine for protection against cisplatin and three-hour paclitaxel-induced neurotoxicity: a Phase II study of the Gynecology and Oncology Group. J. Clin. Oncol (2003) 21(22):4207-4213.
78. HOPENSHAW H, BEAMON K, SYNOLD TW et al.: Neurophysiological study of neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin. Canc. Res. (2004) 10(2):461-467.
79. CAVALETTI G, MINOIA C, SCHIEPPATI M, TREDICI G: Protective effects of glutathione in cisplatin neurotoxicity in rats. Int. J. Radiat. Oncol. Biol. Phys. (1994) 29(4):771-776.
80. TEDESCHI M, DE CESARE A, ORIANA S et al.: The role of glutathione in combination with cisplatin in the treatment of ovarian cancer. Cancer Treat. Rev. (1991) 18(4):253-259.
81. CASCINU S, CORDELLA L, DEL FERRO E et al.: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J. Clin. Oncol. (1995) 13(1 ):26-32.
82. SMYTH JF, BOWMAN A, PERREN T et al.: Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann. Oncol. (1997) 8(6):569-573.
83. CASCINU S, CATALANO V, CORDELLA L et al.: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized double-blind placebo-controlled trial. J. Clin. Oncol. (2002) 20 16):3478-3483.
84. BIEBER LL: Carnitine. Ann. Rev. Biochem. (1988) 57 2):261-283.
85. LOWITT S, MALONE JI, SALEM AF, KORTHACS J, BENFORD S: Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metab. Clin. Exp. (1995) 44 5):677-680.
86. DI GIULIO AM, LESMA E, GORIO A: Diabetic neuropathy in the rat: 1. ALCAR augments the reduced levels and axoplasmic transport of substance P. J. Neurosci. Res. (1995) 40(3):414-419.
87. KANO M, KAWAKAMI T, HORI H et al.: Effects of ALCAR on the fast axoplasmic transport in cultured sensory neurons of streptozotocin-induced diabetic rats. Neurosci. Res. (1999) 33 3):207-213.
88. PISANO C, PRATESI G, LACCABUE D et al.: Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin. Cancer Res. (2003) 15(15):5756-5767.
89. MAESTRI A, DE PASQUALE CERATTI A, CALANDRI C et al.: Acetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathy. Proc. Am. Soc. Clin. Oncol. (2002) 21:247b.
90. POSTMA TJ, HEIMANS JJ: Grading of chemotherapy-induced peripheral neuropathy. Ann. Oncol. (2000) 11(5):509-513.
91. POSTMA TJ, HEIMANS JJ, MULLER MJ, OSSENKOPPELE GJ, VERMORKEN JB, AARONSON NK: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann. Oncol. (1998) 9(7):739-744.
92. KRARUP C. Pitfalls in electrodiagnosis. J. Neurol. (1999) 246(12):1115-1126.
93. ZASLANSKY R, YARNITSKY D: Clinical applications of quantitative sensory testing (QST). J. Neurol. Sci. (1998) 153 3):215-238.
94. CAVALETTI G, BOGLIUN G, MARZORATI L et al.: Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology (2003) 61(9):1297-1300.
95. CHAUDHRY V, ROWINSKY EK, SARTORIUS SE, DONEHOWER RC, CORNBLATH DR: Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann. Neurol. (1994) 35(3):304-311.
96. CHAUDHRY V, EISENBERGER MA, SINIBALDI VJ, SHEIKH K, GRIFFIN JW, CORNBLATH DR: A prospective study of suramin-induced peripheral neuropathy. Brain (1996) 119(Pt6):2039-2052.
97. CORNBLATH DR, CHAUDHRY V, CARTER K et al.: Total neuropathy score. Validation and reliability study. Neurology (1999) 53(8):1660-1664.
98. CHAUDHRY V, CHAUDHRY M, CRAWFORD TO, SIMMONS-O'BRIEN E, GRIFFIN JW: Toxic neuropathy in patients with pre-existing neuropathy. Neurology (2003) 60(2):337-340.